ORYZF Stock Chart & Stats
$3.34
$0.05(1.45%)
At close: 4:00 PM EDT
$3.34
$0.05(1.45%)
Day’s Range― - ―
52-Week Range$2.60 - $4.10
Previous CloseN/A
Volume500.00
Average Volume (3M)100.00
Market Cap
$229.30M
Enterprise Value$230.85M
Total Cash (Recent Filing)$22.12M
Total Debt (Recent Filing)$7.10M
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding84,332,150
10 Day Avg. Volume0
30 Day Avg. Volume100
Financial Highlights & Ratios
PEG Ratio2.31
Price to Book (P/B)2.19
Price to Sales (P/S)0.00
P/FCF Ratio-95.74
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue54.71
Enterprise Value/Gross Profit58.03
Enterprise Value/Ebitda-35.22
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.11
Revenue Forecast (FY)$10.11M
Bulls Say, Bears Say
Bulls Say
Balance Sheet FlexibilityLow leverage and a larger asset and equity base give Oryzon more financial flexibility than many development-stage businesses. This capital position can help support ongoing research and clinical programs while reducing immediate dependence on debt financing.
Proprietary Epigenetics PlatformA proprietary epigenetics focus provides a defined scientific platform rather than a single undifferentiated product concept. Targeting oncology and CNS disorders with high unmet need creates multiple potential development avenues, although clinical validation remains necessary.
Improving Cash-Burn TrendThe reduction in operating and free-cash-flow losses during 2025 is an encouraging directional change for a research-intensive company. If sustained, better cash control could extend financial flexibility and reduce the pace at which additional capital is required.
Bears Say
Persistent UnprofitabilityPersistent operating and net losses show that Oryzon has not yet converted its development activities into a profitable business. Continued losses can constrain reinvestment capacity, increase reliance on financing, and make future earnings power dependent on successful clinical progress.
Volatile Revenue BaseRepeated zero-revenue years and irregular revenue sources make Oryzon’s commercial income difficult to forecast. This instability limits visibility into operating scale, weakens the foundation for recurring growth, and leaves financial performance sensitive to non-recurring or infrequent receipts.
Ongoing Cash BurnNegative operating and free cash flow indicate that the company cannot currently fund operations and development internally. Continued cash burn may require additional capital before products generate meaningful revenue, creating financial pressure even with modest balance-sheet leverage.
Oryzon Genomics SA News
ORYZF FAQ
What was Oryzon Genomics SA’s price range in the past 12 months?
Oryzon Genomics SA lowest stock price was $2.60 and its highest was $4.10 in the past 12 months.
What is Oryzon Genomics SA’s market cap?
Oryzon Genomics SA’s market cap is $229.30M.
When is Oryzon Genomics SA’s upcoming earnings report date?
Oryzon Genomics SA’s upcoming earnings report date is Mar 04, 2027 which is in 124 days.
How were Oryzon Genomics SA’s earnings last quarter?
Oryzon Genomics SA released its earnings results on Jul 27, 2026. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.063 by $0.063.
Is Oryzon Genomics SA overvalued?
According to Wall Street analysts Oryzon Genomics SA’s price is currently Overvalued.
Does Oryzon Genomics SA pay dividends?
Oryzon Genomics SA does not currently pay dividends.
What is Oryzon Genomics SA’s EPS estimate?
Oryzon Genomics SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oryzon Genomics SA have?
Oryzon Genomics SA has 84,332,150 shares outstanding.
What happened to Oryzon Genomics SA’s price movement after its last earnings report?
Oryzon Genomics SA reported an EPS of $0 in its last earnings report, beating expectations of -$0.063. Following the earnings report the stock price went down -1.174%.
Which hedge fund is a major shareholder of Oryzon Genomics SA?
Currently, no hedge funds are holding shares in ORYZF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oryzon Genomics SA
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases; and ORY-4001, a selective HDAC-6 inhibitor for the treatment of neurological disorders, such as Charcot-Marie-Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and others. It also has collaborations in precision medicine with Columbia University in New York and the Institute of Medical and Molecular Genetics (INGEMM) at La Paz Hospital in Madrid psychometrically characterize patients with mutations in the SetD1A or Shank3 genes; and Cooperative Research and Development Agreement (CRADA) to sponsor several clinical trials. The company was incorporated in 2000 and is based in Cornellà de Llobregat, Spain.
Technical Analysis
Ownership Overview
―
Insiders
0.11% Mutual Funds
― Other Institutional Investors
99.78% Public Companies and
Individual Investors